Skip to main content

sirexatamab

Generic: DKN-01·Code: DKN-01

sirexatamab: sourced relationships with 1 company · 1 clinical trial tracked.

sirexatamab evidence translation

What we can confirm

What it means

Source-backed records connect sirexatamab to CYPH; that link alone does not prove the drug works.

What to watch

Watch trial status, endpoints, and the next source-backed update.
BioSniper AIPage evidence connected

Prepared research question

How could sirexatamab → CYPH affect its developer, and what evidence supports the link?

Run cited research

Traceable citations · Unknowns marked

See linked entities and source evidence2 indications · 0 study sponsors

Study sponsors

No additional listed-company sponsor is linked.

Dated Pipeline Records (1)
CompanyDated record stage
CYPHERPUNK TECHNOLOGIES INC. (CYPH)
developer · Reported 2026-03-16 · Current development: unknownSource
colorectal cancer
Phase 2
Clinical Trial Registry Records (1)

Phase 2 Study Evaluating the Efficacy of the Combination of DKN-01 (DKK1 Inhibitor, Leap Therapeutics) and Pembrolizumab in the Treatment of Advanced or Recurrent Endometrial Cancer

NCT05761951Registry updated 2026-02-11·Phase 2
Active, not recruiting

Primary endpoint: ). Incidence of Adverse Events, Graded According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version (v) 5.0

InterventionalRandomizedopen8 targetStarted 2023-08Completion 2029-011 site · United StatesM.D. Anderson Cancer Center

Frequently asked questions

Which companies have sourced relationships with sirexatamab?

sirexatamab has dated SEC/FDA relationship records for CYPHERPUNK TECHNOLOGIES INC..

How many clinical trials involve sirexatamab?

BioSniper tracks 1 clinical trial involving sirexatamab.